Tonix's TONMYA Shows Strong Phase 3 Results for Fibromyalgia Pain Relief
Event summary
- Tonix presented Phase 3 RESILIENT study data for TONMYA at the Non-Opioid Pain Therapeutics Summit on January 29, 2026.
- TONMYA demonstrated a statistically significant reduction in fibromyalgia pain (p<0.0001) with an effect size of 0.38 compared to placebo.
- The study included 456 participants across 34 U.S. sites, showing improvements in sleep disturbance, fatigue, and Fibromyalgia Impact Questionnaire-Revised scores.
- TONMYA was well tolerated with minimal impact on weight or blood pressure and a low discontinuation rate (6.1% vs. 3.5% for placebo).
- The sublingual formulation bypasses first-pass metabolism, optimizing parent-drug exposure during sleep.
The big picture
Tonix's Phase 3 data for TONMYA underscores the growing demand for non-opioid pain treatments amid a chronic pain crisis. With over 10 million fibromyalgia patients in the U.S., the drug's differentiated pharmacokinetic profile and strong efficacy metrics could reshape the market. The strategic focus on bypassing first-pass metabolism aligns with broader industry trends toward optimized drug delivery systems for better patient outcomes.
What we're watching
- Market Differentiation
- Whether TONMYA's unique sublingual formulation and favorable tolerability profile can position it as a leading non-opioid alternative for fibromyalgia.
- Regulatory Approval
- The pace at which Tonix can secure additional approvals or expand indications for TONMYA beyond fibromyalgia.
- Commercialization Strategy
- How Tonix plans to scale the commercial rollout of TONMYA, given its status as the first new prescription medicine for fibromyalgia in over 15 years.
Our editorial coverage:
Related topics